Skip to main content

Advertisement

Log in

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387–91.

    Article  CAS  PubMed  Google Scholar 

  2. Nanni C, Farsad M, Zamagni E, Castellucci P, Cangini D, Montini G, et al. Evaluation of bone lesions in patients with multiple myeloma: comparison between 18F-FDG PET/CT and 11C-Choline PET/CT. Eur J Nucl Med Mol Imaging 2006;33 Suppl 2:188.

    Google Scholar 

  3. Cimitan M, Borsatti E, Tatta R, Drigo A, Rampin L, Rubello D. Uptake of 18F-Fluorocholine (FCH) by bone metastases of prostate cancer: what’s the best timing for PET FCH acquisition? J Nucl Med 2005;46 Suppl 2:432.

    Google Scholar 

  4. Cimitan M, Borsatti E, Tatta R, Drigo A, Rampin L, Rubello D. Timing for 18F-fluorocholine PET/CT acquisition in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2005;32 Suppl 1:160.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marino Cimitan.

Additional information

This reply refers to the letter to the editor at http://dx.doi.org/10.1007/s00259-007-0401-x

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cimitan, M., Bortolus, R., Morassut, S. et al. Reply. Eur J Nucl Med Mol Imaging 34, 1318–1319 (2007). https://doi.org/10.1007/s00259-007-0402-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0402-9

Keywords

Navigation